GW Henssler & Associates Ltd. Sells 14,098 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

GW Henssler & Associates Ltd. lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 6.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 193,297 shares of the medical equipment provider's stock after selling 14,098 shares during the quarter. Zimmer Biomet comprises approximately 1.6% of GW Henssler & Associates Ltd.'s holdings, making the stock its 23rd largest holding. GW Henssler & Associates Ltd. owned 0.09% of Zimmer Biomet worth $23,524,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Impax Asset Management Group plc raised its stake in Zimmer Biomet by 6.9% during the fourth quarter. Impax Asset Management Group plc now owns 4,601 shares of the medical equipment provider's stock worth $560,000 after purchasing an additional 297 shares during the period. Sequoia Financial Advisors LLC raised its position in Zimmer Biomet by 37.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider's stock valued at $18,981,000 after purchasing an additional 42,539 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Zimmer Biomet by 16.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,760,021 shares of the medical equipment provider's stock worth $335,895,000 after buying an additional 386,019 shares during the period. International Assets Investment Management LLC raised its stake in shares of Zimmer Biomet by 11,244.9% in the 4th quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider's stock valued at $8,146,000 after acquiring an additional 66,345 shares during the period. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its holdings in Zimmer Biomet by 1.8% in the 4th quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 9,838 shares of the medical equipment provider's stock valued at $1,197,000 after purchasing an additional 177 shares during the last quarter. Institutional investors own 88.89% of the company's stock.

Insiders Place Their Bets

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now directly owns 44,145 shares in the company, valued at $5,677,929.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.95% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently issued reports on ZBH. Canaccord Genuity Group reiterated a "hold" rating and issued a $130.00 price objective on shares of Zimmer Biomet in a report on Friday, February 23rd. TheStreet raised Zimmer Biomet from a "c" rating to a "b-" rating in a report on Thursday, February 8th. JPMorgan Chase & Co. upped their price objective on Zimmer Biomet from $115.00 to $125.00 and gave the company a "neutral" rating in a research note on Friday, February 9th. Royal Bank of Canada restated an "outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 9th. Finally, StockNews.com cut shares of Zimmer Biomet from a "strong-buy" rating to a "buy" rating in a research note on Monday, February 19th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $139.39.

Zimmer Biomet Price Performance

Shares of ZBH traded down $1.68 during mid-day trading on Wednesday, reaching $127.72. 823,294 shares of the company's stock were exchanged, compared to its average volume of 1,499,804. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $149.25. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The company has a 50-day simple moving average of $126.72 and a two-hundred day simple moving average of $118.66. The company has a market cap of $26.24 billion, a price-to-earnings ratio of 26.46, a PEG ratio of 2.33 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts' consensus estimates of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to analysts' expectations of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The business's revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.88 earnings per share. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.75%. Zimmer Biomet's dividend payout ratio (DPR) is 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.